Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
Wesana Health (WESA) may expand the indication of its psilocybin formulation after meeting with the FDA. In addition to treating anxiety related to traumatic brain injury, it could also target depression. A $3M private placement will fund phase Ib/IIa depression study next year.